HPLC purity
Reverse-phase HPLC with UV detection; ≥99% area purity target on each production lot.
Vial illustrations reflect supplied lyophilized format. Lot codes are sample identifiers; production lots carry their own batch references.
| Compound | Sermorelin (GHRH 1-29) |
|---|---|
| Synonyms | GRF (1-29), Geref |
| Molecular weight | ≈ 3357.9 g/mol |
| Form | Lyophilized powder, sterile glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 5 mg, 15 mg (custom on request) |
| Documentation | COA + HPLC + MS, per-batch lot file |
| Storage | 2–8 °C protected from light; long-term −20 °C |
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 50 vials | 3–7 days |
| Production lot | 200–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Sermorelin searches were up 233% YoY in 2025 — clinic demand is real. Add it to the quote builder for a precise reply within 4 business hours.
Documentation
COA, HPLC chromatogram, MS identity confirmation, water content and storage notes. Buyer track and destination are confirmed before invoicing.
Reverse-phase HPLC with UV detection; ≥99% area purity target on each production lot.
Mass spectrometry confirmation against the sermorelin (GHRH 1-29) reference profile.
Lot code printed on vial label and reflected in the document pack. Reorders cite prior lot for continuity.
FAQ
Sermorelin is a 29-amino-acid GHRH analog studied for growth-hormone axis support. Med spas, longevity clinics and 503A pharmacies source lyophilized sermorelin for in-clinic protocols and individualized compounding.
Sample lots from 50 vials; production lots from 200 vials with tier pricing. Repeat OEM orders are scheduled in 1,000-vial batches.
Patient and clinic interest in growth-hormone axis support has expanded as med spa and longevity programs adopt structured peptide protocols. Sermorelin search volume tracked +233% YoY in 2025 reporting.
Yes. Neutral or branded labels, carton design, document packs, and lot-code handling for repeat OEM supply. See the OEM service path for the full process.
Yes — 503A pharmacies receive context-specific documentation. We do not supply 503B outsourcing facilities for compounds restricted under the FDA's 2026 503B bulks list proposal.
Related compounds